Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment (2024 - 2025)
Phathom Pharmaceuticals (PHAT) posted quarterly Asset Writedowns and Impairment of -$539000.0 for Q4 2025, down 549.17% year-over-year from $120000.0 in Q4 2024, and down 573.75% quarter-over-quarter from -$80000.0 in Q2 2025.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Asset Writedowns and Impairment for 2 consecutive years, with -$539000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment fell 549.17% year-over-year to -$539000.0; the TTM figure through Jun 2026 stood at -$539000.0 (down 138.17% YoY), while the FY2025 annual figure was $280000.0, down 66.51% from the prior year.
- Asset Writedowns and Impairment slipped to -$539000.0 in Q4 2025 per PHAT's latest filing, from -$80000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $899000.0 in Q1 2025 and bottomed at -$539000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -539,000.00 |
| Jun 30, 2025 | -80,000.00 |
| Mar 31, 2025 | 899,000.00 |
| Dec 31, 2024 | 120,000.00 |
| Sep 30, 2024 | 473,000.00 |
| Jun 30, 2024 | 243,000.00 |